US Patent:
20110256098, Oct 20, 2011
Inventors:
David Apelian - Boonton Township NJ, US
Richard C. Duke - Denver CO, US
Alex Franzusoff - Denver CO, US
International Classification:
A61K 38/21
A61P 31/14
A61P 37/04
A61K 39/29
A61P 1/16
US Classification:
424 857, 4242281, 424 854, 4241921, 4241891
Abstract:
Disclosed are uses of immunotherapeutic compositions in combination with Standard of Care (SOC), or interferon therapy combined with anti-viral therapy, for the improved treatment of chronic hepatitis C virus (HCV) infection and related conditions, including liver function. The compositions, kits and uses of the invention, as compared to the use of SOC therapy alone: improves the rate of early response to therapy as measured by early virologic markers (e.g., RVR and EVR), enlarges the pool of patients who will have sustained responses to therapy over the long term, offers shortened courses of therapy for certain patients, enables “rescue” of patients who are non-responders or intolerant to SOC therapy, improves liver function and/or reduces liver damage in patients, and enables the personalization of HCV therapy for a patient, which can result in dose sparing, improved patient compliance, reduced side effects, and improved long term therapeutic outcomes.
